[박은주 제작] Photo composition/illustration
(Brussels = Yonhap News) Correspondent Kim Jong-un = The European Medicines Agency (EMA) announced on the 26th (local time) that Korean biopharmaceutical manufacturer Celltrion’s new coronavirus infection (Corona 19) antibody treatment’Recyrona’ (regdanvimab CT-) P59) can be used for the treatment of COVID-19 in adult patients who do not need oxygen therapy and are at high risk of developing severe disease, Reuters reported.
EMA said the review was conducted prior to marketing approval to help individual countries make decisions about the availability of the drug.
The companion review is a procedure to quickly evaluate promising drugs or vaccines in public health emergencies such as the global epidemic of COVID-19. The companion review will serve as the basis for future applications for EU marketing approval.
EMA said the results of the first section of ongoing study data suggest that Rekirona may lower hospitalization rates, but added that the findings are not strong enough at this stage to reach definitive conclusions about the benefits of the drug.
Celltrion’s antibody treatment, Rekironaju, received conditional approval from the Ministry of Food and Drug Safety on the 5th as a “Korean No. Since the 17th, it has been supplied to medical institutions nationwide.
Unauthorized reproduction-redistribution prohibited>
2021/03/26 22:09 sent